Notably, the recently uncovered roles of xCT in OSA, where it supports redox balance, and sustains OSA cell survival and proliferation under metabolic stress [20,21], position xCT as both a metabolic vulnerability and a promising immunotherapeutic target for OSA. Here, SLC7A11 is linked to obstructive sleep apnea syndrome.